GlaxoSmithKline Pharmaceuticals has announced completion of its transaction with Novartis India today where GSK India acquires Novartis' vaccines business and divests its marketed oncology portfolio to Novartis India.
Shares of select pharmaceutical companies Sun Pharma Advanced Research Company (SPARC), Wockhardt, GlaxoSmithKline Pharmaceuticals, Indoco Remedies and Natco Pharma have rallied between 5-10% on back of heavy volumes in otherwise subdued market on BSE.
Health food drink major GlaxoSmithKline Consumer Healthcare is planning to expand its reach in the country by penetrating the rural markets and adding one million more stores to its existing network of around 2.7 million stores in next 18 months.
The multi-billion dollar three-way deal of Novartis with GlaxoSmithKline (GSK) and Eli Lilly is likely to trigger merger control approvals from various anti-trust authorities, including a scrutiny by Competition Commission of India (CCI), industry
Swiss drug major Novartis’ multi-billion-dollar overhaul through deals with two multinational firms — GlaxoSmithKline (GSK) and Eli Lilly — is likely to have an impact on the Indian market, too, as all the three companies have
GlaxoSmithKline's $1-billion open offer to raise stake in its Indian arm, GlaxoSmithKline Pharmaceuticals, had received a shot in the arm from foreign institutional investors (FII), shareholding data for the March quarter showed.
GlaxoSmithKline Pharmaceuticals today posted 42.87% decline in its net profit at Rs 96.54 crore for the first quarter ended March 31, 2014, as the company continued to be impacted by the revamped price control order.